This approval makes Eli Lillys oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug for weight loss available in pill form, after Wegovy, which gained approval in December 2025
Ex vivo studies using isolated human islets indicated that metformin is capable of augmenting insulin secretion at high glucose concentrations (16.6 mmol/l) [34]
Zore, T., Palafox, M., & Reue, K
TOUJEO should be used 1 time each day and at the same time each day
Supporting GLP-1 Users with PURIS Pea Protein At PURIS, we recognize the growing need for high-quality protein options that align with the evolving dietary habits of GLP-1 users